KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash & Equivalents for 15 consecutive years, with $128.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 85.27% to $128.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.4 million through Dec 2025, up 85.27% year-over-year, with the annual reading at $128.4 million for FY2025, 85.27% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $128.4 million at Supernus Pharmaceuticals, down from $151.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $255.6 million in Q1 2021, with the low at $24.7 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $120.1 million, with a median of $113.6 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 85.75% in 2023, then soared 377.92% in 2025.
  • Over 5 years, Cash & Equivalents stood at $203.4 million in 2021, then tumbled by 54.23% to $93.1 million in 2022, then fell by 19.4% to $75.1 million in 2023, then fell by 7.63% to $69.3 million in 2024, then soared by 85.27% to $128.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $128.4 million, $151.4 million, and $144.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.